Immunological Adverse Effects of Anticonvulsants

Aarli JA. Changes in serum immunoglobulin levels during phenytoin treatment of epilepsy. Acta Neurologica Scandinavica 54: 423–430, 1976a Aarli JA. Drug-induced IgA deficiency in epileptic patients. Archives of Neurology 33: 296–299, 1976b Aarli JA. Phenythoin-induced depression of salivary IgA and gingival hyperplasia. Epilepsia 17: 283–291, 1976c Aarli JA. Phenytoin-induced depression of salivary IgA. Acta Otolaryngologica 82: 199–201, 1976d Aarli JA, Tönder O. Effect of antiepileptic drugs on serum and salivary IgA. Scandinavian Journal of Immunology 4: 391–396, 1975 Adams JD. Localized cutaneous pseudolymphoma associated with phenytoin therapy: a case report. Australasian Journal of Dermatology 22: 28–29, 1981 Adams LE, Hess EV. Drug-related lupus: incidence, mechanisms and clinical implications. Drug Safety 6: 431–449, 1991 Alarcón-Segovia D, Palacios R. Differences in immunoregulatory T cell circuits between diphenylhydantoin-related and spontaneously occurring systemic lupus erythematosus. Arthritis and Rheumatism 24: 1086–1092, 1981 Alberto P, Cougn R, Maurice P, Weber J. Trois cas de lymphome malin ou pseudolymphome chez des épileptiques traités par la diphénylhydantoïne. Schweizerische Medizinische Wochenschrift 101: 1773–1774, 1971 Amadori G, Fiore D. Problemi diagnostici dell’immunopatia idantoinica. Minerva Medica 75: 2503–2519, 1984 Andersen P, Mosekilde L. Immunoglobulin levels and autoantibodies in epileptics on long-term anticonvulsant therapy. Acta Medica Scandinavica 201: 69–74, 1977 Anderson VM, Bauer HM, Kelly AP. Mucocutaneous lymph node syndrome in an adult receiving diphenylhydantoin. Cutis 23: 493–498, 1979 Anthony JJ. Malignant lymphoma associated with hydantoin drugs. Archives of Neurology 22: 450–454, 1970 Arneborn P, Palmblad J. Drug-induced neutropenia: a survey for Stockholm 1973–1978. Acta Medica Scandinavica 212: 289–292, 1982 Arora PK, Hanna EE, Paul SM, Skolnik P. Suppression of the immune response by benzodiazepine receptor inverse agonists. Journal of Neuroimmunology 15: 1–9, 1987 Askmark H, Wiholm B. Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurologica Scandinavica 81: 131–140, 1990 Bardana EJ, Gabourel JD, Anderson CJ, Davies GH. Phenytoininduced suppression of IgA and IgE. Journal of Allergy and Clinical Immunology 65: 167, 1980 Bardana EJ, Gabourel JD, Davies GH, Graig S. Effects of phenytoin on man’s immunity. Evaluation of changes in serum immunoglobulins, complement, and antinuclear antibody. American Journal of Medicine 74: 289–296, 1983 Basaran N, Kansu E, Hincal F. Serum immunoglobulins, complement levels and lymphocyte subpopulations in phenytoin-treated epileptic patients. Immunopharmacology and Immunotoxicology 11: 335–346, 1989 Bassanini M, Baez A, Sotelo J. Immunoglobulins in epilepsy. Journal of Neurological Sciences 56: 275–281, 1982 Bercel NA, Finesilver B, Solomon P, Somerfeld-Ziskind E, Ziskind E. Mesantoin in epilepsy. Journal of the American Medical Association 143: 1460–1462, 1950 Black DM, Fivenson DP. Case report of antiepileptic drug hypersensitivity reaction: pseudolymphoma syndrome. Family Practice Research Journal 8: 107–111, 1989 Bladé Creixenti J, Segura Porta F, Noguéxarau S, Soriano Marín E, García San Miguel J. Asociación de enfermedad de Hodgkin e hidantoínas. Comunicación de un nuevo caso y revisión de la literatura. Medicina Clínica (Barcelona) 15: 24–26, 1980 Blanco A, Palencia R, Solis P. Transient phenytoin-induced IgA deficiency and permanent IgE increase. Allergologia et Immunopathologia 14: 535, 1986 Blijham GH, Blaauw I, Schutte B, Mendes de Leon DE. Increased numbers of suppressor-cytotoxic cells in a patient with carbamazepine hypersensitivity. Journal of Immunopharmacology 6: 79–85, 1984 Boissier MC, Sansonetti P, Dupont B, Lapresle C. Intolérance majeure à la carbamazépine: immunodépression acquise ou allergie? Semaine des Hôpitaux (Paris) 59: 2989–2990, 1983 Botta M, Capra Marzani M, Pavesi M. Linfoadenopatia angioim-munoblastica con disprotidemia (L.A.I.D.) e carbamazepina: a proposito di un caso. Gazzetta Medica Italiana — Archivio Scienze Mediche 144: 711–716, 1985 Bradley JM, Sagraves R, Kimbrough AC. Carbamazepine-induced thrombocytopenia in a young child. Clinical Pharmacy 4: 221–223, 1985 Brandt L, Nilsson PG. Lymphocytopenia in patients treated with phenytoin. Lancet 1: 308, 1976 Burks AW, Charlton R, Casey P, Poindexter A, Steele R. Immune function in patients treated with phenytoin. Journal of Child Neurology 4: 25–29, 1989 Charlesworth MEN. Phenytoin-induced pseudolymphoma syndrome: an immunologic study. Archives of Dermatology 113: 477–480, 1977 Chennebault JM, Dumont AM, Achard J, Alquier P, Saint-André JP. Insuffisance rénale aiguë, érythrodermie, polyadénopathies au cours d’un traitement par carbamazépine. Thérapie 37: 103–108, 1982 Choovivathanavanich P, Wallace EM, Scaglione PR. Pseudolymphoma induced by diphenylhydantoin. Journal of Pediatrics 76: 621–623, 1970 Cohen BL, Bovasso GJ. Leukopenia as an unusual component of diphenylhydantoin hypersensitivity: a case with pruritus, rash, fever, lymphadenopathy, but low leukocyte count. Clinical Pediatrics 12: 622–623, 1973 Cooke LE, Hardin TC, Hendrickson DJ. Phenytoin-induced pseudolymphoma with mycosis fungoides manifestations. Clinical Pharmacy 7: 153–157, 1988 Coope R, Burrows RGR. Treatment of epilepsy with dipheny-lhydantoinate. Lancet 1: 490–492, 1940 Danno K, Kume M, Ohta M, Utani A, Ohno S, et al. Erythroderma with generalized lymphadenopathy induced by phenytoin. Journal of Dermatology 16: 392–396, 1989 Davies-Jones GAB. Anticonvulsants. In Dukes MNG (Ed.) Meyler’s side effects of drugs, 11th ed., pp. 120–136, Elsevier, Amsterdam, 1988 De Marco P, Melchiori G. Carbamazepine and eosinophilia. Annals of Neurology 20: 274, 1986 Descotes J. Immunotoxicology of drugs and chemicals, 2nd ed., Elsevier, Amsterdam, 1988 Descotes J. Drug-induced immune diseases, Elsevier, Amsterdam, 1990 Dorfman RF, Warnke R. Lymphadenopathy simulating the malignant lymphomas. Human Pathology 5: 519–550, 1974 Dosch H-M, Jason J, Gelfand EW. Transient antibody deficiency and abnormal T suppressor cells induced by phenytoin. New England Journal of Medicine 306: 406–409, 1982 Duggan MAK, Court JB. A proposed mechanism of production of the autoimmune and lymphoproliferative side-effects of β-adrenergic-site-blocking drugs and hydantoin anticonvulsants. Annals of Clinical Research 13: 406–418, 1981 Eeg-Olofsson O, Janjua NA, Andermann E, Guttmann RD, Osterland K. Immunological and genetic studies in primary generalized corticoreticular epilepsy. Acta Neurologica Scandinavica 74: 425–431, 1986 Ferrer Sancho J, Martínez Vázquez JM, Capdevila Morell JA, Ocaña I, Pigrau C, et al. Gammapatía monoclonal transitoria en el curso de una linfadenopatía angioimmunoblástica. Medicina Clinica (Barcelona) 84: 458, 1985 Flowers FP, Araujo OE, Hamm KA. Phenytoin hypersensitivity syndrome. Journal of Emergency Medicine 5: 103–108, 1987 Fontana A, Grob PJ. Immunodeficiency in epilepsy: a new view. Journal of Neurology 220: 297–301, 1979 Fontana A, Grob PJ, Sauter R. Immunoglobulin abnormalities in relatives of IgA-deficient epileptic. Journal of Neurology 217: 207–212, 1978a Fontana A, Grob PJ, Sauter R, Joller H. IgA deficiency, epilepsy and hydantoin medication. Lancet 2: 228–231, 1976 Fontana A, Joller H, Skvaril F, Grob PJ. Immunological abnormalities and HLA antigen frequencies in IgA deficient patients with epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry 41: 593–597, 1978b Fossan GO. Reduced CSF IgG in patients treated with phenytoin (diphenylhydantoin). European Neurology 14: 426–432, 1976 Fried MP, Sunwoo Y. Anticonvulsant-induced lymphoma. Laryngoscope 84: 1770–1781, 1974 Fujimoto Y, Ikoma R, Shimizu T, Shimizu A. Effect of zonisamide on serum immunoglobulins. Arzneimittel-Forschung 40: 855–858, 1990 Gabourel JD, Davies GH, Bardana EJ, Ratzlaff NA. Phenytoin influence on human lymphocyte mitogen response: a prospective study of epileptic and nonepileptic patients. Epilepsia 23: 367–376, 1982 Gabrys K, Medras E, Kowalski P, Gola A. Wystapienie chloniaka zlosliwego w przebiegu leczenia przeciwdrgawkowego. Polski Tygodnik Lekarski 38: 505–507, 1983 Gams RA, Neal JA, Conrad FG. Hydantoin-induced pseudopseudolymphoma. Annals of Internal Medicine 69: 557–568, 1968 Garzon P, Gonzalez-Cornejo S, Hernandez-Hernandez G, Aguirre-Portillo L, Almodovar-Cuevas C, et al. Effects of antiepileptic drugs on concentrations of serum proteins and immunoglobulins of epileptic patients. General Pharmacology 17: 49–55, 1986 Gaulier A, Marsan C, Sigal S, Perron J, Loutre JC. Lymphadénopathie dysimmunitaire, érythrodermie et troubles hématologiques au cours d’un traitement par la carbamazépine. Nouvelle Presse Médicale 9: 1388, 1980 Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, et al. Familial occurrence of hypersensitivity to phenytoin. American Journal of Medicine 91: 631–634, 1991 Gerson WT, Fine DG, Spielberg SP, Sensenbrenner LL. Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro. Blood 61: 889–893, 1983 Gilhus NE. The in vitro effect of phenytoin and carbamazepine on subpopulations of human blood mononuclear cells. International Journal of Immunopharmacology 5: 283–288, 1983 Gilhus NE. Effect of phenytoin and carbamazepine on subpopulations of mononuclear blood cells as defined by membranc antigens. International Archives of Allergy and Applied Immunology 74: 80–83, 1984 Gilhus NE, Aarli JA. The reversibility of phenytoin-induccd IgA deficiency. Journal of Neurology 226: 53–61, 1981a Gilhus NE, Aarli JA. Respiratory disease and nasal immunoglobulin concentrations in phenytoin-treated epileptic patients. Acta Neurologica Scandinavica 63: 34–43, 1981b Gilhus NE, Aarli JA, Thorsby E. HLA antigens in epileptic patients with drug-induced immunodeficiency. International Journal of Immunopharmacology 4: 517–520, 1982a Gilhus NE, Lea T. Carbamazepine: effect on IgG subclasses in epileptic patients. Epilepsia 29: 317–320, 1988 Gilhus NE, Matre R. Carbamazepine effects on mononuclear blood cells in epileptic patients. Acta Neurologica Scandinavica 74: 181–185, 1986 Gilhus NE, Matre R, Aarli JA. Lymphocyte subpopulations and lymphocyte function in phenytoin-treated patients with epilepsy. International Journal of Immunopharmacology 4: 43–48, 1982b Gilhus NE, Strandjord RE, Aarli JA. The effect of carbamazepine on serum immunoglobulin concentrations. Acta Neurologica Scandinavica 66: 172–179, 1982c Gleichman HIK, Pals ST, Radaszkiewicz T. T cell-dependent B-cell proliferation and activation induced by administration of the drug diphenylhydantoin to mice. Hematological Oncology 1: 165–176, 1983 Gouet D, Rouffineau J, Pouget-Abadie JF, Besson I, Becq-Giraudon B. Lymphadénopathie dysimunitaire survenant au cours d’un traitement par la carbamazépine: deux observations. Revue de Médecine Interne 5: 72–74, 1984 Grindulis KA, Nichol FE, Oldham R. Phenytoin in rheumatoid arthritis. Journal of Rheumatology 13: 1035–1039, 1986 Grob PJ, Herold GE. Immunological abnormalities and hydantoins. British Medical Journal 2: 561–563, 1972 Guerra IC, Fawcett WA IV, Redmon AH, Lawrence EC, Rosenblatt HM, et al. Permanent intrinsic B cell immunodeficiency caused by phenytoin hypersensitivity. Journal of Allergy and Clinical Immunology 77: 603–608, 1986 Hadzic N, Portman B, Davies ET, Mowal AP, Mieli-Vergani G. Acute liver failure induced by carbamazepine. Archives of Disease in Childhood 65: 315–317, 1990 Haldorsen T, Aarli JA. Immunoglobulin concentrations in first-degree relatives of epileptic patients with drug-induced IgA deficiency. Acta Neurologica Scandinavica 56: 608–612, 1977 Halevy S, Feuerman EJ. Pseudolymphoma syndrome. Dermatologica 155: 321–327, 1977 Haruda F. Phenytoin hypersensitivity: 38 cases. Neurology 29: 1480–1485, 1979 Herberman RB. Natural killer cells and their possible roles in host resistance against tumors. Transplantation Proceedings 16: 476–478, 1984 Huijgens PC, Thijs LG, Den Ottolander GJ. Pure red cell aplasia, toxic dermatitis and lymphadenopathy in a patient taking diphenylhydantoin. Acta Haematologica 59: 31–36, 1978 Hyman GA, Sommers SC. The development of Hodgkin’s disease and lymphoma during anticonvulsant therapy. Blood 28: 416–427, 1966 Hyman LR, Ballow M, Knieser MR. Diphenylhydantoin interstitial nephritis: roles of cellular and humoral immunologic injury. Journal of Pediatrics 92: 915–920, 1978 Iivanainen M, Syriänen J, Waltimo O, Valtonen VV. Increased bacterial antibody titres and IgA deficiency in epileptic patients. British Medical Journal 294: 677, 1987 Isobe T, Tomita M, Matsumoto J, Itoh T, Fujita T. Haematologic and immunologic aberrations in patients under diphenylhydantoin administration. Acta Haematologica Japonica 46: 1–5, 1983 Jain KK. Systemic lupus erythematosus (SLE)-like syndromes associated with carbamazepine therapy. Drug Safety 6: 350–360, 1991 Josephs SH, Rothman SJ, Buckley RH. Phenytoin hypersensitivity. Journal of Allergy and Clinical Immunology 66: 166–172, 1980 Joubert PH, Aucamp AK, Potgieter GM, Verster F. Epilepsy and IgA deficiency: the effect of sodium valproate. South African Medical Journal 52: 642–644, 1977 Jungi WF, Senn HJ, Stanisic M, Rösli R. Maligne Lymphome nach jahrelanger Epilepsiebehandlung mit Hydantoinpräparaten? Schweizerische Medizinische Wochenschrift 105: 1735–1737, 1975 Kahn HD, Faguet GB, Agee JF, Middleton HM. Drug-induced liver injury: in vitro demonstration of hypersensitivity to both phenytoin and phenobarbital. Archives of Internal Medicine 144: 1677–1679, 1984 Kanoh T, Uchino H. Immunodeficiency and epilepsy. Lancet 1: 860–861, 1976 Katzin WE, Julius CJ, Tubbs RR, McHenry MC. Lymphoproliferative disorders associated with carbamazepine. Archives of Pathology and Laboratory Medicine 114: 1244–1248, 1990 Khayat D, Marty M, Brocheriou C, Jacquillat C. Lymphome non hodgkinien après maladie de Hodgkin chez un malade recevant des hydantoïnes. Nouvelle Presse Médicale 35: 2637–2638, 1982 Kleckner HB, Yakulis V, Heller P. Severe hypersensitivity to diphenylhydantoin with circulating antibodies to the drug. Annals of Internal Medicine 83: 522–523, 1975 Kornberg A, Kobrin I. IgG antiplatelet antibodies due to carbamazepine. Acta Haematologica 68: 68–70, 1982 Lapes MJ, Vivacqua RJ, Antoniades K. Immunoblastic lymphadenopathy associated with phenytoin (diphenylhydantoin). Lancet 24: 198, 1976 Leppik IE, Lapora J, Lowenson R. Seasonal incidence of phenytoin allergy unrelated to plasma levels. Archives of Neurology 42: 120–122, 1985 Li FP, Willard DR, Goodman R, Vawter G. Malignant lymphoma after diphenylhydantoin (Dilantin) therapy. Cancer 36: 1359–1362, 1975 Lillie MA, Yang LC, Honig PJ, August CS. Erythroderma, hypogammaglobulinemia, and T-cell lymphocytosis: occurrence following therapy with phenytoin. Archives of Dermatology 119: 415–418, 1983 MacFarlane DG, Clark B, Panayi GS. Pilot study of phenytoin in reumathoid arthritis. Annals of the Rheumatic Diseases 45: 954–956, 1986 MacICinney AA, Booker HE. Diphenylhydantoin effects on human lymphocytes in vitro and in vivo. Archives of Internal Medicine 129: 988–992, 1972 MacKinney AA, Knobeloch L. Diphenylhydantoin inhibits cortisol-induced lysis of thymocytes. Proceedings of the Society for Experimental Biology and Medicine 182: 474–477, 1986 MacKinney AA, Vyas R. The assay of diphenylhydantoin effects on growing human lymphocytes. Journal of Pharmacology and Experimental Therapeutics 186: 37–43, 1973 Maguire JH, Wettrell G, Rane A. Apparently normal phenytoin metabolism in a patient with phenytoin-induced rash and lymphadenopathy. British Journal of Clinical Pharmacology 24: 554–557, 1987 Marcoli M, Gatti G, Ippoliti G, Lombardi M, Crema A, et al. Effect of chronic anticonvulsant monotherapy on lymphocyte subpopulations in adult epileptic patients. Human Toxicology 4: 147–157, 1985 Margaretten NC, Hincks JR, Warren RP, Coulombe Jr RA. Effects of phenytoin and carbamazepine on human natural killer cell activity and genotoxicity in vitro. Toxicology and Applied Pharmacology 87: 10–17, 1987 Massimo L, Pasino M, Rosanda-Vadalà C, Tonini GP, De Negri M, et al. Immunological side-effects of anticonvulsants. Lancet 1: 860, 1976 Matson JR, Krous HF, Blackstock R. Diphenylhydantoin-induced hypersensensitivity reaction with interstitial nephritis. Human Pathology 16: 94–97, 1985 Matzner Y, Polliack A. Lymphoproliferative disorders in four patients receiving chronic diphenylhydantoin therapy: etiologic correlation or chance association? Israel Journal of Medical Sciences 14: 865–869, 1978 McCarthy LJ, Aguilar JC, Ransburg R. Fatal benign phenytoin lymphadenopathy. Archives of Internal Medicine 139: 367–368, 1979 Meissner O, Joubert HF, Joubert PH, Van der Meyden CH, Studzinski W. IgA in epileptics receiving anticonvulsivant therapy. European Journal of Clinical Pharmacology 25: 491–495, 1983 Meissner O, Joubert PH, Joubert HF, Van der Merwe CA. The IgA immune system in epileptics on anticonvulsant therapy. European Journal of Clinical Pharmacology 27: 81–83, 1984 Menitove JE, Rassiga AL, McLaren GD, Daniel TM, Mahmoud AAF. Antigranulocyte antibodies and deranged immune function associated with phenytoin-induced serum sickness. American Journal of Rheumatology 10: 277–284, 1981 Michael JR, Mitch WE. Reversible renal failure and myositis caused by phenytoin hypersensitivity. Journal of the American Medical Association 236: 2773–2775, 1976 Moutard ML, Bavoux F, Mensire A, Lebourges F, Ponsot G. Nephrite tubulo-interstitielle immuno-allergique secondaire à la prise de carbamazépine. Archives Françaises de Pédiatrie 44: 191–193, 1987 Murphy JE, Stewart RB, Springer PK. Carbamazepine-induced leukocytosis. American Journal of Hospital Pharmacy 37: 550–552, 1980 Murphy JM, Mashman J, Miller JD, Bell JB. Suppression of carbamazepine-induced rash with prednisone. Neurology 41: 144–145, 1991 Musolino R, Natoli M, Gallitto G, Morgante L, Serra S, et al. The effect of chronic n-dipropylacetamide (Depamide) treatment on plasmatic immunoglobulins of epileptic patients. Acta Neurologica 35: 115–120, 1980 Neilan BA, Leppik IE. Phenytoin and formation of T lymphocyte rosettes. Archives of Neurology 37: 580–581, 1980 Newcom SR, Kadin ME. T-cell leukemia with thymic involution. Cancer 43: 622–626, 1979 Oates RK, Tonge RE. Phenytoin and the pseudolymphoma syndrome. Medical Journal of Australia 2: 371–373, 1971 Okamoto Y, Shimizu K, Tamura K, Yamada M, Matsui Y, et al. Effects of anticonvulsants on cellular immunity (in Japanese). No To Shinkei 41: 299–304, 1989 O’Keane JC. Non Hodgkin lymphoma and carbamazepine. Lancet 2: 1275–1276, 1989 Olsson R, Zettergren L. Anticonvulsant-induced liver damage. American Journal of Gastroenterology 83: 576–577, 1988 Öner A, Topaloglu R, Besbas N, Topaloglu H. Carbamazepine induced systemic lupus erythematosus: another warning. Clinical Neurology and Neurosurgery 92–3: 261–262, 1990 Pacifici R, Paris L, Di Carlo S, Pichini S, Zuccaro P. Immunologie aspects of carbamazepine treatment in epileptic patients. Epilepsia 32: 122–127, 1991 Paladini G, Marinig L. Effetti collaterali immunoallergici indotti dalla somministrazione di carbamazepina: contribute casistico. Minerva Medica 75: 1651–1655, 1984 Pelekanos J, Camfield P, Camfield C, Gordon K. Allergic rash due to antiepileptic drugs: clinical features and management. Epilepsia 32: 554–559, 1991 Pellock JM. Carbamazepine side effects in children and adults. Epilepsia 28 (Suppl. 3): S64–S70, 1987 Penarrocha Diago M, Antolin Rodriguez MA, Alfaro Giner A, Perez Sirvent ML. [Hematologic alterations and reduction in serum folate in epileptics treated with anticonvulsants]. Neurologia 4: 119–123, 1989 Pereira A, Cervantes F, Rozman C. Anemia macrocitica por deficit de ácido fólico y linfoma no hodgkiniano asociados a la ingesta prolongada de difenilhidantoina. Medicina Clínica (Barcelona) 85: 503–505, 1985 Pisciotta AV. Carbamazepine: hematologic toxicity. In Woodbury DM (Ed.) Antiepileptic drugs, pp. 533–541, Raven Press, New York, 1982 Prosser TR, Lander RD. Phenytoin-induced hypersensitivity reactions. Clinical Pharmacy 6: 728–734, 1987 Puppo F, Adami GF, Corsini G, Zavarise GM, Zattoni J. Effect of a single oral dose of phenobarbitone on lymphocyte blastogenic response in man. British Journal of Anaesthesia 52: 1205–1207, 1980 Rausing A, Trell E. Malignant lymphogranulomatosis and anticonvulsant therapy. Acta Medica Scandinavica 189: 131–136, 1971 Reents SB, Luginbuhl WE, Davis SM. Phenytoin-carbamazepine cross-sensitivity. Drug Intelligence and Clinical Pharmacy 23: 235–236, 1989 Reiffers J. Les pseudo-lymphomes et les lymphomes induits par les hydantoïnes. Nouvelle Revue Française d’Hématologie 20: 131–138, 1978 Ricevuti G, Marcoli M, Gatti G, Mazzone A, Lecchini S, et al. Assessment of polymorphonucleate leucocyte functions in adult epileptic patients undergoing long-term phenytoin treatment. Human Toxicology 5: 237–241, 1986 Rosenthal CJ, Noguera CA, Coppola A, Kapeiner SN. Pseudolymphoma with mycosis fungoides manifestations, hyperresponsiveness to diphenylhydantoin, and lymphocyte disregulation. Cancer 49: 2305–2314, 1982 Rouffineau J, Besson I, Brechoire D, Lebezu M, Pouget-Abadie JF, et al. Lymphadénopathie angio-immunoblastique induite par la carbamazépine: à propos d’une observation d’évolution spontanément favorable. Archives de Médecine de l’Ouest 13: 446, 1981 Ruff ME, Pincus LG, Sampson HA. Phenytoin-induced IgA depression. American Journal of Diseases of Children 141: 858–861, 1987 Saltzstein SL, Ackerman LV. Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically and pathologically malignant lymphoma. Cancer 12: 164–182, 1959 Schlaifer D, Arlet P, Oilier S, Montane P, Le Tallec Y, et al. Carbamazepine update. Lancet 2: 980–981, 1989 Schlumpf M, Ramseier H, Lichtensteiger W. Prenatal diazepam induced persisting depression of cellular immune response. Life Sciences 44: 493–501, 1989 Schoenfeld Y, Ben Baruch N, Livni E, Santo M, Pinkhas J. Carbamazepine (Tegretol)-induced thrombocytopenia. Acta Haematologica 68: 74, 1982 Schweiger F-J, Kelton JG, Messner H, Klein M, Berger S, et al. Anticonvulsant-induced marrow suppression and immune thrombocytopenia. Acta Haematologica 80: 54–58, 1988 Schwinghammer TL, Howrie DL. Phenytoin-induced lymphadenopathy. Drug Intelligence and Clinical Pharmacy 17: 460–462, 1983 Seager J, Jamison DL, Wilson J, Hayward AR, Soothill JF. IgA deficiency, epilepsy and phenytoin treatment. Lancet 2: 632–635, 1975 Seetharam MN, Pellock JM. Risk-benefit assessment of carbamazepine in children. Drug Safety 6: 148–158, 1991 Severson GS, Harrington DS, Burnett DA, Linder J. Dermatopathic lymphadenopathy associated with carbamazepine: a case mimicking a lymphoid malignancy. American Journal of Medicine 83: 597–599, 1987 Seyfeddinipur N. Lymphoadenopathie bei Phenytoin-Behandlung. Deutsche Medizinische Wochenschrift 101: 1454–1456, 1976 Shakir RA, Behan PO, Dick H, Lambie DG. Metabolism of immunoglobulin A, lymphocyte function, and histocompatibility antigens in patients on anticonvulsants. Journal of Neurology, Neurosurgery, and Psychiatry 41: 307–311, 1978 Shuttleworth D, Graham-Brown RAC, Williams AJ, Cambell AC, Sewell H. Pseudo-lymphoma associated with carbamazepine. Clinical and Experimental Dermatology 9: 421–423, 1984 Silverman AK, Fairley J, Wong RC. Cutaneous and immunologic reactions to phenytoin. Journal of the American Academy of Dermatology 18: 721–741, 1988 Singsen BH, Fishman L, Hanson V. Antinuclear antibodies and lupus-like syndromes in children receiving anticonvulsants. Pediatrics 57: 529–534, 1976 Sinnige HAM, Boender CA, Kuypers EW, Ruitenberg HM. Carbamazepine-induced pseudolymphoma and immune dysregulation. Journal of Internal Medicine 227: 355–358, 1990 Sinues B, Conde B, Martinez P, Cisterna R. Repercussion of antiepileptic treatment with phenobarbitone and phenytoin on some parameters of immunity: comparative study. International Journal of Immunopharmacology 4: 328, 1982 Sisca TS. An unusual dual hypersensitivity reaction induced by diphenylhydantoin. American Journal of Hospital Pharmacy 30: 446–449, 1973 Slavin BN, Fenton GM, Laundy M, Reynolds EH. Serum immunoglobulins in epilepsy. Journal of Neurological Sciences 23: 353–357, 1974 Smith QT, Hamilton MJ, Biros MH, Pihlstrom BL. Salivary and plasma IgA of seizure subjects receiving phenytoin. Epilepsia 20: 17–23, 1979 Smythe MA, Umstead GS. Phenytoin hepatotoxicity: a review of the literature. Drug Intelligence and Clinical Pharmacy 23: 13–18, 1989 Sorrell TC, Forbes IJ. Depression of immune competence by phenytoin and carbamazepine. Studies in vivo and in vitro. Clinical and Experimental Immunology 20: 273–285, 1975 Sorrell TC, Forbes IJ, Burness FR, Rischbieth RHC. Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydantoin). Lancet 2: 1233–1235, 1971 Spiers EM, Potts RC, Simpson JRM, MacConnachie A, Beck JA. Mechanisms by which barbiturates suppress lymphocyte responses to phytohaemagglutinin stimulation. International Journal of Immunopharmacology 9: 505–512, 1987 Stanley J, Fallon-Pellicci V. Phenytoin hypersensitivity reaction. Archives of Dermatology 114: 1350–1353, 1978 Strandjord RE, Johannessen SI, Aarli JA. Serum concentrations of immunoglobulins in patients with epilepsy treated with carbamazepine. Acta Neurologica Scandinavica 61: 260–263, 1980 Stroink AR, Skillrud DM, Kiely JM, Sundt Jr TM. Carbamazepine-induced hemolytic anemia. Acta Haematologica 72: 346–348, 1984 Talesnik E, Rivero SJ, Gonzalez B. Serum IgA deficiency induced by prolonged phenytoin treatment. Revista de Investigación Clinica 41: 331–335, 1989 Tartara A, Verri AP, Nespoli L, Moglia A, Botta MG. Immunological findings in epileptic and febrile convulsion patients before and under treatment. European Neurology 20: 306–311, 1981 Tasaka K, Terao R, Uokawa M, Miyake H, Kamei C. Immunological studies on delayed hypersensitivity to phenytoin-II: the delayed skin reaction induced by BSA-phenytoin conjugate. International Journal of Immunopharmacology 9: 401–409, 1987 Thatcher N, Wan HH, Swindell R, Wilkinson PM, Crowther D. Effects of diphenylhydantoin on killer cell activity and other immunological functions: a sequential study including the interaction of Corynebacterium parvum in melanoma patients. International Journal of Immunopharmacology 4: 167–174, 1982 Tomsick RS. The phenytoin syndrome. Cutis 32: 535–541, 1983 Travin M, Macris NT, Block JM, Schwimmer D. Reversible common variable immunodeficiency syndrome induced by phenytoin. Archives of Internal Medicine 149: 1421–1422, 1989 Tsung SH, Lin JI. Angioimmunoblastic lymphadenopathy in a patient taking diphenylhydantoin. Annals of Clinical and Laboratory Science 11: 542–545, 1981 Valli M, Jadot G, Bussiere H, Bouyard P. Immunoglobulines sé-riques et traitement par la phénytoïne. Thérapie 37: 694–695, 1982 Vellucci A, Galanti G, Pezzella B, De Longis P, Colacecchi C. Su un caso di pseudo-linfoma esantematico da ipersensibilità alla difenilidantoina, con transitorio deficit immunologico. Clinica Terapeutica 94: 229–237, 1980 Verdier F, Brouland JP, Virat M, Descotes J. Phénytoine et test du ganglion poplité chez le rat Sprague Dawley. Journal de Toxicologie Clinique et Expérimentale 10: 161–167, 1990 Vesin P, Periac P, Kalifat R, Intrator L, Tulliez M, et al. Lymphadénopathie et anomalies protidiques après traitement par la phénylhydantoïne. Nouvelle Presse Médicale 5: 1125–1127, 1976 Webster RO, Goldstein IM, Flick MR. Selective inhibition by phenytoin of chemotactic factor-stimulated neutrophil functions. Journal of Laboratory and Clinical Medicine 103: 22–33, 1984 Weedon AP. Diphenylhydantoin sensitivity: a syndrome resembling infectious mononucleosis with a morbilliform rash and cholestatic hepatitis. Australian and New Zealand Journal of Medicine 5: 561–563, 1975 Wilden JN, Scott CA. A pseudolymphomatous reaction in soft tissue associated with phenytoin sodium. Journal of Clinical Pathology 31: 761–764, 1978 Wolf R, Kahane E, Sandbank M. Mycosis fungoides-like lesions associated with phenytoin therapy. Archives of Dermatology 121: 1181–1182, 1985 Yates P, Stockdill G, Mclntyre M. Hypersensitivity to carbamazepine presenting as pseudolymphoma. Journal of Clinical Pathology 39: 1224–1228, 1986 Zimmer JP, Lehr HA, Kornhuber ME, Breitig D, Montagnier L, et al. Diphenylhydantoin (DPH) blocks HIV-receptor on T-lymphocyte surface. Blut 53: 447–450, 1986